Clinical Trials Logo

Advanced Malignant Solid Tumor clinical trials

View clinical trials related to Advanced Malignant Solid Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06166472 Not yet recruiting - Clinical trials for Advanced Malignant Solid Tumor

A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

Start date: December 12, 2023
Phase: Phase 1
Study type: Interventional

This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor

NCT ID: NCT05911984 Not yet recruiting - Clinical trials for Advanced Malignant Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Start date: June 30, 2023
Phase: Phase 1
Study type: Interventional

This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.

NCT ID: NCT04275050 Not yet recruiting - Clinical trials for Advanced Malignant Solid Tumor

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets

Start date: April 2020
Phase: Phase 1
Study type: Interventional

TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6). Based on current research, overexpression of positive regulatory proteins in the cell cycle is one of the important reasons for resistance to endocrine therapy. CDK4 / 6 is the key regulators of the cell cycle inhibiting tumor cell proliferation.